Cellosaurus logo
expasy logo

Cellosaurus NPC-B13 (CVCL_D3FG)

[Text][XML][JSON]
Cell line name NPC-B13
Accession CVCL_D3FG
Resource Identification Initiative To cite this cell line use: NPC-B13 (RRID:CVCL_D3FG)
Comments Group: Patented cell line.
Registration: International Depositary Authority, American Type Culture Collection (ATCC); PTA-127019.
Population: Chinese; Taiwan.
Characteristics: Established from a patient-derived xenograft established in NOD/SCID mice (PubMed=34204797).
Transformant: NCBI_TaxID; 10376; Epstein-Barr virus (EBV).
Derived from site: Metastatic; Bone; UBERON=UBERON_0002481.
Disease Nasopharyngeal carcinoma (NCIt: C3871)
Nasopharyngeal carcinoma (ORDO: Orphanet_150)
Species of origin Homo sapiens (Human) (NCBI Taxonomy: 9606)
Sex of cell Male
Age at sampling 52Y
Category Cancer cell line
STR profile Source(s): Patent=US20220373534

Markers:
AmelogeninX
CSF1PO10,11
D1S165611,16,17
D2S44112,14
D2S133818,23
D3S135816
D5S81811
D7S82011
D8S117912
D10S124813,15
D12S39119,23
D13S3178
D16S5399
D18S5115
D19S43314,14.2
D21S1129,30
D22S104516
FGA27
Penta D8,12
Penta E15
TH017
TPOX8,11
vWA14,16

Run an STR similarity search on this cell line
Publications

PubMed=34204797; DOI=10.3390/cancers13122954; PMCID=PMC8231497
Hsin-Pai Li, Chen-Yang Huang, Kar-Wai Lui, Yin-Kai Chao, Chun-Nan Yeh, Li-Yu Lee, Yen-Lin Huang, Tung-Liang Lin, Yung-Chia Kuo, Mei-Yuan Huang, Yi-Ru Lai ...Show all 20 authors... , Yuan-Ming Yeh, Hsien-Chi Fan, An-Chi Lin, Jason Chia-Hsun Hsieh, Kai-Ping Chang, Chien-Yu Lin, Hung-Ming Wang, Yu-Sun Chang, Cheng-Lung Hsu; Show fewer authors
Combination of epithelial growth factor receptor blockers and CDK4/6 inhibitor for nasopharyngeal carcinoma treatment.
Cancers (Basel) 13:2954.1-2954.18(2021)

Patent=US20220373534
Cheng-Lung Hsu;
Human nasopharyngeal carcinoma cells derived from patient derived xenograft and uses thereof.
Patent number US20220373534, 24-Nov-2022

Cross-references
Encyclopedic resources Wikidata; Q127382966
Entry history
Entry creation30-Jan-2024
Last entry update10-Apr-2025
Version number3